TY - JOUR
T1 - Herpes zoster in children with bone marrow transplantation
T2 - Report from a single institution
AU - NAKAYAMA, HIDEKI
AU - OKAMURA, JUN
AU - OHGA, SHOUICHI
AU - MIYAZAKI, CHIAKI
AU - MATSUZAKI, AKINOBU
AU - IKUNO, YOSHIKO
AU - UEDA, KOHJI
AU - TASAKA, HIDEKO
PY - 1995/6
Y1 - 1995/6
N2 - Herpes zoster (HZ) has been often observed after bone marrow transplantation (BMT) in childhood. The occurrence of HZ was reviewed in children who received BMT. The clinical features of HZ were reviewed in 44 children who underwent BMT at Kyushu Cancer Center. Among the 35 recipients with a history of varicella before BMT, several factors associated with BMT and the lymphocyte subsets were compared between the patients who developed HZ (HZ + group) and those who did not (HZ‐ group). Twenty‐two recipients (50%) developed HZ; in two‐thirds of these cases (15/22: 68%), HZ occurred between 80 and 120 days after BMT (median 101 days). The recipients treated with busulfan had a higher occurrence of HZ than those treated without it. The patients with Grade II‐IV acute graft‐versus‐host disease (GVHD) developed HZ more frequently. In the HZ + group, the absolute number of lymphocytes, CD3+, CD4+ or CD8+ cells at 3 months was significantly lower than that observed at 12 months after BMT and the CD4/CD8 ratio was significantly lower at 1 month than after 3 months of BMT. In conclusion, recipients were susceptible to HZ at around 100 days after BMT. The development of HZ may be associated with unbalanced T lymphocytes at that time. 1995 Japan Pediatric Society
AB - Herpes zoster (HZ) has been often observed after bone marrow transplantation (BMT) in childhood. The occurrence of HZ was reviewed in children who received BMT. The clinical features of HZ were reviewed in 44 children who underwent BMT at Kyushu Cancer Center. Among the 35 recipients with a history of varicella before BMT, several factors associated with BMT and the lymphocyte subsets were compared between the patients who developed HZ (HZ + group) and those who did not (HZ‐ group). Twenty‐two recipients (50%) developed HZ; in two‐thirds of these cases (15/22: 68%), HZ occurred between 80 and 120 days after BMT (median 101 days). The recipients treated with busulfan had a higher occurrence of HZ than those treated without it. The patients with Grade II‐IV acute graft‐versus‐host disease (GVHD) developed HZ more frequently. In the HZ + group, the absolute number of lymphocytes, CD3+, CD4+ or CD8+ cells at 3 months was significantly lower than that observed at 12 months after BMT and the CD4/CD8 ratio was significantly lower at 1 month than after 3 months of BMT. In conclusion, recipients were susceptible to HZ at around 100 days after BMT. The development of HZ may be associated with unbalanced T lymphocytes at that time. 1995 Japan Pediatric Society
UR - http://www.scopus.com/inward/record.url?scp=84986973736&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84986973736&partnerID=8YFLogxK
U2 - 10.1111/j.1442-200X.1995.tb03319.x
DO - 10.1111/j.1442-200X.1995.tb03319.x
M3 - Article
C2 - 7645377
AN - SCOPUS:84986973736
SN - 1328-8067
VL - 37
SP - 302
EP - 307
JO - Pediatrics International
JF - Pediatrics International
IS - 3
ER -
